These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 18927241

  • 1. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
    Mao ZL, Wheeler JJ, Clohs L, Beatch GN, Keirns J.
    J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter.
    Mao ZL, Townsend RW, Gao Y, Wheeler JJ, Kastrissios H, Keirns J.
    J Clin Pharmacol; 2012 Jul; 52(7):1042-53. PubMed ID: 21659624
    [Abstract] [Full Text] [Related]

  • 3. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Retyk E, Drenning DH, Atrial Arrhythmia Conversion Trial (ACT-III) Investigators.
    Am J Cardiol; 2010 Nov 01; 106(9):1277-83. PubMed ID: 21029824
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
    Mao Z, Wheeler JJ, Townsend R, Gao Y, Kshirsagar S, Keirns JJ.
    J Pharmacokinet Pharmacodyn; 2011 Oct 01; 38(5):541-62. PubMed ID: 21786177
    [Abstract] [Full Text] [Related]

  • 5. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG, Roos JS, Kavanagh KM, Dickinson G.
    Am Heart J; 2010 Jun 01; 159(6):1095-101. PubMed ID: 20569725
    [Abstract] [Full Text] [Related]

  • 6. Vernakalant in the management of atrial fibrillation.
    Cheng JW.
    Ann Pharmacother; 2008 Apr 01; 42(4):533-42. PubMed ID: 18334607
    [Abstract] [Full Text] [Related]

  • 7. Disposition and mass balance of [14C]vernakalant after single intravenous and oral doses in healthy volunteers.
    Mao ZL, Alak A, Wheeler JJ, Keirns J.
    Drug Metab Lett; 2011 Apr 01; 5(2):114-25. PubMed ID: 21457140
    [Abstract] [Full Text] [Related]

  • 8. [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
    Hirt MN, Eschenhagen T.
    Dtsch Med Wochenschr; 2010 May 01; 135(19):971-6. PubMed ID: 20446233
    [Abstract] [Full Text] [Related]

  • 9. Vernakalant hydrochloride for the treatment of atrial fibrillation.
    Kozlowski D, Budrejko S, Lip GY, Mikhailidis DP, Rysz J, Raczak G, Banach M.
    Expert Opin Investig Drugs; 2009 Dec 01; 18(12):1929-37. PubMed ID: 19938903
    [Abstract] [Full Text] [Related]

  • 10. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C, Raev DH, Dickinson G, Butterfield NN, Mangal B, Beatch GN.
    Circ Arrhythm Electrophysiol; 2011 Oct 01; 4(5):637-43. PubMed ID: 21841207
    [Abstract] [Full Text] [Related]

  • 11. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.
    Roy D, Rowe BH, Stiell IG, Coutu B, Ip JH, Phaneuf D, Lee J, Vidaillet H, Dickinson G, Grant S, Ezrin AM, Beatch GN, CRAFT Investigators.
    J Am Coll Cardiol; 2004 Dec 21; 44(12):2355-61. PubMed ID: 15607398
    [Abstract] [Full Text] [Related]

  • 12. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS, Jang IJ, Kim BH, Kim J, Jeon JY, Tae YM, Yi S, Eum S, Cho JY, Shin SG, Yu KS.
    Clin Ther; 2010 Apr 21; 32(4):659-66. PubMed ID: 20435235
    [Abstract] [Full Text] [Related]

  • 13. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
    Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Stevenson R, Gonzalez MD.
    Expert Opin Investig Drugs; 2008 May 21; 17(5):805-10. PubMed ID: 18447605
    [Abstract] [Full Text] [Related]

  • 14. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.
    Torp-Pedersen C, Camm AJ, Butterfield NN, Dickinson G, Beatch GN.
    Int J Cardiol; 2013 Jun 05; 166(1):147-51. PubMed ID: 22108512
    [Abstract] [Full Text] [Related]

  • 15. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
    Duggan ST, Scott LJ.
    Drugs; 2011 Jan 22; 71(2):237-52. PubMed ID: 21275448
    [Abstract] [Full Text] [Related]

  • 16. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
    Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A, Toft E, Atrial Arrhythmia Conversion Trial Investigators.
    Circ Arrhythm Electrophysiol; 2009 Dec 22; 2(6):652-9. PubMed ID: 19948506
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN, Mangal B.
    BMC Cardiovasc Disord; 2016 May 28; 16():113. PubMed ID: 27233239
    [Abstract] [Full Text] [Related]

  • 18. Atrial selective effects of intravenously administered vernakalant in conscious beagle dogs.
    Bechard J, Pourrier M.
    J Cardiovasc Pharmacol; 2011 Jul 28; 58(1):49-55. PubMed ID: 21753258
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA.
    Clin Pharmacol Ther; 2004 Dec 28; 76(6):536-44. PubMed ID: 15592325
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
    Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI.
    J Clin Psychopharmacol; 2009 Feb 28; 29(1):39-43. PubMed ID: 19142106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.